Navigation Links
Immunosuppressive drug shows promise in treatment of eye disorder

It is a routine practice to prescribe drugs called immunosuppressant to transplant patients to prevent the transplanted organs from being rejected. The medical community has only been interested in worrying about the problems caused due to immunosuppression. Looking at the other side of the coin, there seems to be benefits as well.//

It has been found out that the immunosuppressive drug mycophenolate mofetil, used to prevent rejection of transplanted hearts, kidneys and livers, may also be effective in controlling inflammatory eye diseases. "The drug seemed to be effective even in patients who had failed treatment from other immunosuppressive drugs," says lead author Jennifer E. Thorne, M.D., an assistant professor of ophthalmology.

Physicians gave the drug to 84 patients, of whom 61 percent had uveitis (intraocular inflammation), 17 percent had scleritis (inflammation of the outer wall of the eye), 11 percent had mucous membrane pemphigoid (a condition causing scarring of the eyelids) and 11 percent had inflammation behind the eye or in other areas.

Patients took two pills each morning and two each evening, for a total dose of 2 grams daily. Thirty-six patients (43 percent) already had been treated with at least one other immunosuppressive drug.

The results revealed that 81 patients (97 percent) had control of their ocular inflammation after one month of treatment. Eighty-two percent of patients had control of their inflammation and were able to taper their dose of the steroid prednisone to 10 or fewer milligrams daily.

Side effects such as stomach upset or mild diarrhoea warranted the withdrawal of seven patients from the study. However, these side effects can be minimized by reducing the dosage of the drug in most of the cases, which offers a new ray of hope in the treatment of eye disorder.


'"/>




Page: 1

Related medicine news :

1. Immunosuppressive Action Of Fungal Metabolite - Gliotoxin
2. A Newly Identified Immunosuppressive Protein in Rheumatoid Arthritis
3. Gene Therapy shows promise in treating Hemophilia
4. Leukemia pill shows promise against stomach cancer
5. Stent shows promise in keeping arteries open
6. Drug to treat lung cancer shows promise
7. Latest drug shows promise in multiple myeloma
8. AIDS vaccine falls short but shows some promise
9. SARS vaccine shows promise in Animal Testing
10. Study shows that interventions from health workers can bring about changes in asthma causes
11. Research shows steady rise in allergic diseases
Post Your Comments:
(Date:12/5/2009)... experts advise , , SATURDAY, Dec. 5 (HealthDay News) -- ... can have bad reactions to certain holiday traditions and ... wheezing, according to the American College of Allergy, Asthma ... live evergreens may choose to decorate with artificial plants, ...
(Date:12/5/2009)... their cleaning processes. The technology available to the lab allows it ... customers relating to cleaning parts, process development, and verification. , ... ... a Jackson, MI-based company, is home to an advanced technology center ...
(Date:12/5/2009)... is a collaborative effort by the National Association ... North America (MANA), Citizens for Midwifery (CfM), International ... of Midwives (NARM), and the Midwifery Education Accreditation ... efforts of The MAMA Campaign to secure federal ...
(Date:12/4/2009)... Dec. 4 Varian Medical Systems (NYSE: VAR ... the regular 2010 Annual Meeting of Stockholders for February 11, ... meeting will be held at the Crowne Plaza Cabana Hotel, ... PT. ,, The meeting will be webcast by Thomson Financial ...
(Date:12/4/2009)... 4 Thousands of KPMG LLP employees came together in ... community service event which combines the audit, tax and advisory ... national service day reflects our firm,s long history of volunteerism. ... of caring to brighten the holidays for some children," said ...
Breaking Medicine News(10 mins):Health News:Keep Asthma, Allergies at Bay for the Holidays 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2
... characteristics help fine-tune treatment, study says , , FRIDAY, Dec. ... predicting breast cancer risk, recurrence risk and response to ... density and tumor size, a panel of experts report. ... Friday at the annual San Antonio Breast Cancer Symposium ...
... [The Washington Post Friday reported that the ... the White House are considering easing the official advisory cautioning ... at the Environmental Protection Agency reportedly are concerned about the ... of several "midnight" rules and policy changes in the pipeline ...
... Dec. 12 Roberta Kalafut, D.O., just announced her resignation ... a close the worst abuses of power by the TMB ... disciplinary actions, particularly against her competitors, and stonewalling by the ... "We applaud Kalafut,s resignation," said AAPS Executive Director ...
... climes becoming more conducive to spread , , FRIDAY, Dec. ... risk for infection with so-called "airport malaria" in malaria-free ... , Here,s how it happens, as the scientists explain ... tropical regions, and at the end of a flight ...
... to consumer-directed plan , , ... to make the most of their money, particularly their health ... 2.0, which helps members manage costs and still keep the ... a high-deductible plan with a health savings account (HSA). This ...
... , SAN ANTONIO, TEXAS - Early-stage breast cancer patients ... significant risk of recurrence of their disease, compared to those ... according to a study led by researchers at The University ... presented today at the CRTC-AACR San Antonio Breast Cancer Symposium, ...
Other Medicine News:Health News:Progress Made in Predicting Breast Cancer Risk 2Health News:Progress Made in Predicting Breast Cancer Risk 3Health News:AAPS Applauds the Resignation of TMB President Roberta Kalafut, Mari Robinson Should Resign Next 2Health News:'Airport Malaria' Risk Rising With Global Warming 2Health News:'Airport Malaria' Risk Rising With Global Warming 3Health News:Regence Unveils New Approach to Healthcare With Launch of HSA Healthplan 2.0 2Health News:Early stage, HER2-positive breast cancer patients at increased risk of recurrence 2Health News:Early stage, HER2-positive breast cancer patients at increased risk of recurrence 3
(Date:12/4/2009)... Suneva Medical, a privately-held aesthetic medical device company, ... President and Chief Financial Officer. In this role, ... administrative functions including finance, accounting, IT, IR, administration and ... Company,s senior management team. ,, "One of my ...
(Date:12/4/2009)... Shore and E. David Crawford presented results for prostate-specific ... end points of biochemical recurrence rate in a Phase ... or monthly leuprolide in prostate cancer patients during the ... received FIRMAGON 240/80 mg/month had a recurrence rate of ...
(Date:12/3/2009)... ACTON, Mass., Dec. 3 Allen Medical Systems, a ... ), today announced the launch of its new Allen ... www.AllenAmatech.com . ,, The website reinforces the ... of the new product catalog, with detailed descriptions and ...
Breaking Medicine Technology:Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2EHE International Supports the National Headache Foundation 48180 1EHE International Supports the National Headache Foundation 48180 2Quest Diagnostics to Speak at the William Blair 26 Company 29th Annual Growth Stock Conference 48179 1Quest Diagnostics to Speak at the William Blair 26 Company 29th Annual Growth Stock Conference 48179 2Senetek PLC Gains Six Year Extension of Rights from Czech Republic Institute of Experimental Botany 48177 1Senetek PLC Gains Six Year Extension of Rights from Czech Republic Institute of Experimental Botany 48177 2Senetek PLC Gains Six Year Extension of Rights from Czech Republic Institute of Experimental Botany 48177 3
... Complete Remission / Unconfirmed Complete Remission Rate 3.5 Fold Higher ... Compared to ... (Nasdaq and MTA: CTIC) announced today that it achieved the ... pixantrone,(BBR2778) for patients with advanced, relapsed aggressive non-Hodgkin,s,lymphoma (NHL) based ...
... Demonstrate Test,s Potential for ... Rapid Uptake, ... Applied Biosystems Inc. (NYSE: ABI ) today,announced the launch of BCtect(TM), ... a unique gene expression signature,identified by DiaGenic using a custom TaqMan(R) Array ...
Other Medicine Technology:Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 2Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 3Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 4Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test 2Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test 3